This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for continuing Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and Visionary Health Concepts.  MEC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Collaborative designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding the accreditation of this activity, please contact Medical Education Collaborative at (303) 420-3252.

Upon completion of this educational activity, participants should be able to:    

• Explain the use of assays to determine coreceptor tropism in treatment-experienced HIV-positive patients

• Identify factors associated with improved response to raltegravir in treatment-experienced HIV-positive patients

• Recognize the predictors of etravirine efficacy in NNRTI-experienced HIV-positive patients

The purpose of this activity is to increase the knowledge and competency of physicians on identifying patients with non-CCR5 tropism and the new drugs approved for use in treatment experienced patients.

The program is intended for physicians and other healthcare providers treating HIV-positive patients, especially those who are seeking clinically-relevant and comprehensive information on viral resistance. Participants should have basic scientific knowledge and understanding of HIV disease and its treatment.

This activity is joint sponsored by Visionary Health Concepts and Medical Education Collaborative (MEC).  MEC is a non-profit organization

 that has been certifying quality educational activities since 1988.

Disclaimer: The opinions expressed in this educational activity are those of the faculty and do not reflect the views of Medical Education Collaborative and Visionary Health Concepts. This educational activity may discuss off-label and/or investigational uses and dosages for therapeutic products/procedures that have not been approved by the United States Food and Drug Administration (FDA). Medical Education Collaborative and Visionary Health Concepts do not recommend the use of any product/procedure outside of the labeled indications. A qualified health care professional should be consulted before using any therapeutic product/procedure discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.  Please refer to the official prescribing information for each product/procedures for approved indication, contraindications, and warnings.

This activity was made possible by an unrestricted educational grant from Tibotec Therapeutics.

Medical Education Collaborative adheres to ACCME Essential Areas and Policies, including the Standards for Commercial Support regarding industry support of continuing medical education   In order to resolve any identified conflicts of interest, disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships, as well as the discussion of unlabeled or unapproved use of any drug, device, or procedure by the faculty, are made known below.

In this activity the faculty discloses they will discuss the following investigational drugs in this issue: vicriviroc and elvitegravir. They will not discuss the unlabeled use of any drugs, devices, procedures, or products.

CME Chairperson

Jonathan Schapiro, MD

Director HIV/AIDS, National Hemophelia Center, Israel

Adjunct Clinical Assistant Professor of Medicine (VCF)

Stanford University School of Medicine, Stanford, CA

  Jonathan Schapiro, MD has the following relationships to disclose: research support, honorarium or consulting fees from   

  the following: Abbott, Ambrillia, Bayer, Bristol Myers Squibb, Gilead, Merck, Monogram Biosciences, Pfizer, Roche,

  Siemens, and Tibotec Therapeutics.

Editor

Jacob Lalezari, MD

Medical Director

Quest Clinical Research

Assistant Clinical Professor of Medicine

University of California, San Francisco

Jacob Lalezari, MD has the following relationships to disclose: clinical research support from Boehringer Ingelheim,

GlaxoSmithKline, Koronis, Medarex, Merck, Panacos, Pfizer, Pharmasset, Progenics, Roche and Tibotec.

Editor-in-Chief

               Lillian Thiemann

               President

               Visionary Health Concepts

               Lillian Thiemann has no relationships to disclose.

Writer          

               Anna Poppa

               Contributing Editor

               London, England

               Anna Poppa has the following relationships to disclose: consultant for Pfizer.

Accredited Provider

          Employees of Medical Education Collaborative, the accredited provider for this activity, have

          disclosed that they have no significant financial relationships. 

Read the target audience, objectives, faculty disclosures and accreditation statements, then read the ResistanceWATCH News which is available in print or online, when finished reading all the content complete the  Post Test, credit application and evaluation which is found at the end of the printed program or online at www.freehivinfo.com. You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. To receive your certificate, fax the post test, credit application and evaluation to Visionary Health Concepts FAX: 800-407-2505 or complete the forms online. NOTE: Participants who have successfully completed the online version of this activity are not eligible to receive credit for this print activity.

Medical Education Collaborative (MEC) protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. MEC and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

Medical Education Collaborative (MEC) and Visionary Health Concepts maintain physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright^© Release Date: June 17, 2008 Expiration Date: June 17, 2009 Visionary Health Concepts.  All Rights Reserved.  Permission for accreditation use granted to Medical Education Collaborative (MEC).

 VHConcepts requires version 4.x browsers or higher from Microsoft or Netscape. This program is available online and as an Adobe Acrobat PDF document for easy download. To download a free copy of Acrobat Reader, please click here or visit http://www.adobe.com/products/acrobat/readstep2.html?promoid=BONRM